Yes, for some people, and the evidence is better than most complementary therapies ever manage. Gut-directed hypnotherapy has been tested in randomised trials since 1984, appears in American and British IBS guidelines, and has follow-up data running to five and six years. It is not fringe.
It is also nowhere near as reliable as the internet says it is. The figure repeated across almost every page ranking for this question, that hypnotherapy "improves gut symptoms by 70 to 80%", is a misreading. The underlying numbers describe the proportion of people in an uncontrolled specialist clinic who improved, not the amount their symptoms fell. When independent researchers ran the same treatment against a credible comparison, the gap narrowed sharply.
This guide walks through what gut-directed hypnotherapy is, what each trial actually found, where the famous number came from, which mechanism the research supports and which one the marketing teaches, and the specific situations where it is the wrong tool entirely.
The short answer, with the numbers that actually support it
Gut-directed hypnotherapy works for a substantial minority of people with IBS, and for a smaller share it works dramatically. The original 1984 trial randomised 30 people with severe refractory IBS to hypnotherapy or to psychotherapy plus a placebo pill. The psychotherapy group improved a little on pain, distension and wellbeing but not on bowel habit. The hypnotherapy group improved on everything, with no relapses across three months of follow-up (Whorwell 1984).
Forty years of work followed. A systematic review of the technique found that six of seven randomised IBS studies reported a significant reduction in overall gastrointestinal symptoms, usually compared with supportive therapy, and that response rates among people receiving gut-directed hypnotherapy ranged between 24% and 73% (Peters 2015). That range is the honest headline. It is wide because the trials differ enormously in who they recruited, how many sessions they gave and what they compared against.
The most recent network meta-analysis of behavioural therapies pooled 67 randomised trials and 7,441 participants. Gut-directed hypnotherapy was efficacious against waiting list control, with a relative risk of global symptoms not improving of 0.79 (95% CI 0.66 to 0.95) across 12 trials and 1,507 patients. It also ranked last among the seven therapies that showed efficacy, behind minimal-contact CBT, telephone disease self-management and dynamic psychotherapy. The authors found evidence of publication bias, reported that no trial was at low risk of bias across all domains, and rated certainty in every comparison as low or very low (Thakur 2025). That review declared no funding.
So the accurate sentence is: gut-directed hypnotherapy beats doing nothing, probably beats generic supportive attention, is recommended by guidelines, and is not the most effective behavioural option in head-to-head rankings. The American College of Gastroenterology suggests gut-directed psychotherapy be used to treat global IBS symptoms (Lacy 2021). NICE positions it further down the line, as a referral to consider for people who have not responded to drug treatment after twelve months and who have a continuing symptom profile described as refractory IBS (NICE CG61).
What "gut-directed" means, and why a general hypnotherapist is not the same thing
Gut-directed hypnotherapy is a specific protocol, not relaxation with a gut theme bolted on. After an induction, the therapist uses imagery and suggestion aimed directly at gut sensation and gut function: warmth over the abdomen, a river or a smooth-running mechanism representing intestinal flow, suggestions of reduced pain perception and of the gut behaving calmly. Patients then practise at home, usually daily, with an audio recording.
The best-documented version is the Manchester protocol: twelve weekly one-hour sessions over three months, with required practice between sessions (Gonsalkorale 2002). Other groups use seven to ten sessions, individually or in groups.
This distinction matters because it is the single most common disappointment in patient threads. In one r/ibs discussion about hypnotherapy, several people described seeing a general hypnotherapist and getting nothing gut-specific, with one calling the experience worse than an app (r/ibs thread). Another described sessions with a clinician that were relaxing but changed nothing about their bowel (r/ibs thread). None of the trial evidence applies to generic hypnosis. If you are paying for this, ask which IBS protocol the practitioner uses and how many sessions it runs to.
Where the 70 to 80% figure came from, and what it really counts
This is the number you have read, and it is worth tracing because almost nobody sourcing it has checked it.
The largest single dataset is an audit of 1,000 consecutive patients with refractory Rome II IBS treated with twelve sessions at the Manchester unit. Overall 76% met the primary outcome of a 50-point reduction in the IBS Symptom Severity Score, higher in women (80%) than men (62%), and higher in people with anxiety (79%) than without (71%). The mean fall in symptom severity was 129 points. Pain days fell from 18 to 9 per month, and 67% reported a 30% or greater reduction in abdominal pain (Miller 2015). An earlier audit of the first 250 patients found the same broad picture (Gonsalkorale 2002).
Two things follow. First, 76% is a proportion of people who crossed a threshold, not a percentage by which symptoms fell. A page saying hypnotherapy "improves gut symptoms by 70 to 80%" has converted a headcount into a magnitude. Second, an audit has no control group, so it cannot separate the treatment from time, expectation, regression to the mean and the effect of twelve hours of a clinician's undivided attention.
We checked the pages currently ranking for this question. The most prominent of them states that hypnotherapy improves gastrointestinal symptoms "by 70 to 80%" and attributes it only to "multiple well-controlled studies" with no citation at all. A vendor page for a hypnotherapy app attaches the 70 to 80% claim to a 2012 randomised trial, and a separate "reduce gut symptoms by up to 72%" claim to a 2016 trial. Neither underlying paper says that. The 2012 trial's own stated conclusion is that gut-directed hypnotherapy is effective for refractory IBS but that effectiveness is lower outside highly specialised research centres (Lindfors 2012). The 72% in the 2016 trial is the proportion of participants achieving a 20mm improvement on a symptom scale, and the diet-only arm of the same trial scored 71% (Peters 2016).
That trial is the fairest estimate available of what happens when gut-directed hypnotherapy is offered to ordinary referred patients rather than to a selected specialist caseload, and measured against a control that also gets attention and education. A roughly 24-point absolute gap over supportive therapy is a real, useful treatment effect. It is not 80%.
What the controlled trials found, side by side
| Study | Design | What it compared | Result |
|---|---|---|---|
| Whorwell 1984 | RCT, 30 patients, severe refractory | Hypnotherapy vs psychotherapy plus placebo pill | Hypnotherapy improved all features; difference highly significant |
| Lindfors 2012 | Two RCTs, 138 refractory patients | 12 sessions vs supportive therapy or waiting list | Symptoms improved in hypnotherapy arms only; effect smaller outside research centres |
| Moser 2013 | RCT, 100 refractory patients | 10 group sessions plus usual care vs usual care | 60.8% vs 40.9% improved after treatment; 54.3% vs 25.0% over 15 months |
| Peters 2016 | RCT, 74 patients | Hypnotherapy vs low FODMAP diet vs both | 72%, 71% and 72% improved; no difference between arms |
| Flik 2019 | RCT, 354 referred patients | Individual vs group hypnotherapy vs educational supportive therapy | 40.8% vs 33.2% vs 16.7% adequate relief at 3 months |
| Anderson 2025 | RCT, 240 adults | Digital programme with vs without hypnotherapy | 81% vs 63% reached a 50-point symptom fall |
Two patterns jump out. Hypnotherapy consistently beats a low-attention comparator, and the gap shrinks whenever the comparator is itself a structured, time-matched programme. A meta-analysis of eight randomised trials and 464 patients found hypnosis superior to control for adequate symptom relief at end of therapy, with a number needed to treat of 5, and at long-term follow-up with a number needed to treat of 3. One participant out of 238 in the hypnosis arms dropped out because of an adverse event, a panic attack (Schaefert 2014).
Network meta-analyses agree on placement rather than dominance. An earlier review of 41 trials and 4,072 participants found gut-directed hypnotherapy efficacious, with a relative risk of remaining symptomatic of 0.67 (95% CI 0.49 to 0.91), alongside self-administered and face-to-face CBT, and noted high risk of bias and funnel plot asymmetry (Black 2020). For abdominal pain specifically, face-to-face gut-directed hypnotherapy was among the treatments showing efficacy across 42 trials and 5,220 participants, with no trial at low risk of bias in all domains (Goodoory 2024). A 2026 network meta-analysis that put behavioural therapies and gut-brain neuromodulators in the same network found hypnotherapy superior to waiting list, but ranked behind tricyclic antidepressants and dynamic psychotherapy, again with low or very low certainty throughout (Khasawneh 2026).
The mechanism the marketing teaches, and the mechanism the studies found
Commercial pages usually give a confident story: hypnotherapy improves communication along the vagus nerve and stimulates the parasympathetic nervous system. The published mechanism research does not support that story cleanly, and the researchers themselves are notably more careful.
Three physiological studies point in three directions.
Rectal sensitivity changed in one study. Twenty-three patients were assessed with a barostat before and after twelve weeks of hypnotherapy. Ten were hypersensitive at baseline, seven hyposensitive and six normal. After treatment, the mean pain sensory threshold rose in the hypersensitive group, fell non-significantly in the hyposensitive group, and normal perception was unchanged. The authors concluded hypnotherapy improves abnormal sensory perception while leaving normal sensation alone (Lea 2003).
It did not change in another. In two studies totalling 42 patients with severe IBS receiving seven biweekly sessions plus home audio, all central IBS symptoms improved substantially, yet rectal pain thresholds, rectal smooth muscle tone and autonomic function were unaffected. Somatisation and psychological distress fell sharply, and the authors concluded that hypnosis improved IBS through those routes rather than the physiological ones they measured (Palsson 2002).
The response to eating did change. Twenty-eight refractory patients were randomised to twelve weeks of hypnotherapy or supportive therapy and tested with colonic distension before and after a duodenal lipid infusion. Controls became more sensitive after the fat load across gas, discomfort and pain thresholds; the hypnotherapy group became more sensitive only for pain, and did not show the drop in colonic balloon volume seen in controls. In plain terms, the exaggerated post-meal response was blunted (Simren 2004).
The review that catalogued the technique concluded that its potential mechanisms of action on the brain-gut axis are multiple, spanning psychological effects through to physiological gastrointestinal modifications, and explicitly listed the unanswered questions (Peters 2015). Even the best-ranking consumer page concedes that nobody understands exactly how it works.
That honesty is worth passing on. If you are deciding whether to spend money on this, the useful framing is not "it retrains my vagus nerve" but "in several trials, people like me reported less pain and more settled bowels afterwards, and researchers disagree about why". Our post on whether stress can cause an IBS flare covers the gut-brain pathway itself in detail.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
Does it last, or does it wear off?
Durability is where gut-directed hypnotherapy has an unusually strong hand for a behavioural treatment.
In 204 patients followed prospectively for up to six years after hypnotherapy, 71% responded initially, and 81% of those responders maintained their improvement over time. Most of the remaining 19% described their deterioration as slight. Symptom scores at follow-up were still significantly better than before treatment and barely changed from immediately after it, with no difference between people assessed at one, two, three, four or five-plus years. Quality of life and anxiety or depression scores remained improved but did drift back somewhat. Patients also reported fewer consultations and less medication use (Gonsalkorale 2003).
More recent work replicates the pattern outside the founding centre. A two-year follow-up of 289 people treated with a twelve-week nurse-administered programme found responder proportions of 64.3% after treatment, 62.8% at six months, 64.7% at one year and 61.8% at two years. Younger age, individual rather than group delivery, and more severe baseline symptoms predicted a better response (Lovdahl 2025). In the group trial, benefit over usual care was still present at fifteen months (Moser 2013).
The paediatric data go furthest. Children treated with either therapist-delivered hypnotherapy or standardised home recordings were followed for a median of six years: 86.6% and 80.0% respectively still reported adequate relief (Rexwinkel 2022). The original paediatric trial found successful treatment in 85% of the hypnotherapy group against 25% with standard medical therapy at one year (Vlieger 2007). Those figures are in children with functional abdominal pain or IBS, not adults, and childhood functional abdominal pain has a different natural history, so they are not transferable to an adult deciding about a course of treatment.
Relapse does happen. In the earliest follow-up series, two of fifteen patients relapsed once and were brought back into remission with a single additional session (Whorwell 1987). A recurring theme in patient threads is that benefit faded and people were unsure whether to repeat the programme.
Apps versus a therapist: what the digital trial actually compared
The most-asked practical question is whether an app does the same job. Nobody has compared an app against a therapist head to head in adults, so the honest answer is that it is unknown. What exists is one good randomised trial of an app against a matched digital programme.
240 adults with IBS were randomised to a 42-session daily digital programme either including the gut-directed hypnotherapy component or without it. At completion, 81% of the hypnotherapy group met the primary endpoint of a 50-point or greater fall in symptom severity, against 63% of the active control. A 30% reduction in pain was reported by 71% against 35%, and quality of life improved more with hypnotherapy. Psychological status improved similarly in both groups (Anderson 2025). That trial was funded by Mindset Health Pty Ltd, the company that makes the app being tested, as recorded in the paper's grant listing.
Two readings of that result deserve equal weight. The hypnotherapy component added something real over and above an equally structured daily programme, which is a stronger test than a waiting list. And the control arm's 63% response is a reminder of how much of the benefit comes from doing something deliberate every day for six weeks. Neither arm was blinded, which is the hard structural problem in this field: the Rome Foundation's consensus on behavioural trial design exists precisely because standard drug-trial evaluation methods do not capture what makes a behavioural trial rigorous (Burton-Murray 2025).
Group and remote delivery are being tested for the same reason, cost and availability. A pilot of nurse-led online group hypnotherapy in 51 patients found 53% responded, comparable to the 55% previously seen with on-site group delivery, with benefit sustained at six months (Lovdahl 2026). After twelve remote sessions using the Manchester protocol, 58% of 52 patients reported at least 30% global symptom improvement and 90% would recommend remote delivery, though 39% felt they would have done better in person (Noble 2022).
In r/ibs, experience with the leading hypnotherapy app splits sharply. Several people described finishing the programme and feeling better than they had in years; several completed it faithfully and got nothing; one abandoned it because the volume of notifications and subscription prompts worked against the calm it was selling; and a recurring complaint was losing access to content when the subscription lapsed (r/ibs thread). Our Cara Care review covers the regulated prescription-app route to the same therapy in more depth.
How many sessions, and does daily practice matter?
The classic course is twelve weekly sessions with daily home practice. Shorter courses have now been tested directly. A randomised trial of 448 people with refractory IBS confirmed non-inferiority of six sessions compared with twelve (Hasan 2021); a post hoc analysis of that trial's outcomes reported that 76.3% achieved a 50-point fall in symptom severity and 59.8% a 30% improvement in pain (Devenney 2024).
Course intensity does appear to matter. A meta-analysis examining delivery characteristics found that across seven pooled trials the overall effect of hypnotherapy on global gastrointestinal symptoms was not statistically significant (SMD 0.24, 95% CI -0.06 to 0.54). Within subgroups, higher session frequency of at least one per week (SMD 0.45), higher volume of at least eight sessions with six or more hours of contact (SMD 0.51) and group delivery (SMD 0.45) all showed benefit, and only volume produced a significant difference between subgroups (Krouwel 2021). The practical implication: a short, thin course is the version least likely to help.
The home practice component is not decoration. In children, standardised home recordings used five or more times a week were non-inferior to individual therapist sessions (Rutten 2017), and that non-inferiority held at six years (Rexwinkel 2022). Again, that is paediatric evidence.
A worked example: twelve weeks, tracked properly
Here is what a fair personal trial looks like, using the outcome measures the studies use.
Weeks minus two to zero (baseline). Log every day: number of pain days, worst pain 0 to 10, stool form, urgency episodes, and whether you avoided something you wanted to do. Do not change anything else. The trials' own benchmark is a 50-point fall in IBS Symptom Severity Score or a 30% fall in pain, so you need a before to have an after.
Weeks one to six. Start the course. Practise daily if the protocol asks for it, and record whether you practised, because adherence is the variable most likely to explain a null result. Hold your diet, medication and supplements steady. Do not start a low FODMAP elimination in the same window; if you are planning that, our guide to finding your actual triggers explains why overlapping changes make both uninterpretable.
Week six checkpoint. In the digital trial, most improvement that happened had begun by around this point. Compare your six-week pain days against baseline. No movement at all is information, not failure.
Weeks seven to twelve. Continue if there has been any movement. The specialist audits ran to twelve weeks, and the Krouwel analysis suggests higher-volume courses do better.
Week twelve review. Compare pain days per month, worst pain and urgency episodes against baseline. In the 1,000-patient audit, the average responder went from 18 pain days a month to 9 (Miller 2015). If you have halved pain days, that is a result worth protecting. If nothing has shifted after a full-volume course, stopping is a reasonable decision, and it does not mean you failed at relaxing.
Keeping this kind of before-and-after on paper also makes the next appointment shorter. Clairop is built for exactly this: logging takes seconds, and it produces a one-page summary you can hand to a clinician instead of trying to reconstruct three months from memory. You can see the flow on how it works.
Who responds best, and who tends not to
The predictor data are patchy and mostly come from one centre, but they are consistent enough to be worth knowing.
| Factor | What the data show |
|---|---|
| Sex | Women responded more often than men in the 1,000-patient audit, 80% vs 62% (Miller 2015) |
| Male with diarrhoea-predominant IBS | Improved far less than other subgroups in the 250-patient audit, with no identifiable explanation (Gonsalkorale 2002) |
| Bowel habit subtype | Made no difference to outcome in the larger audit (Miller 2015) or to long-term group outcomes (Moser 2013) |
| Anxiety | Slightly higher response rate in anxious patients, 79% vs 71% (Miller 2015); higher baseline anxiety predicted dropping out (Devenney 2024) |
| Symptom burden | Higher baseline non-colonic symptom scores predicted response (Devenney 2024); more severe baseline symptoms predicted response at two years (Lovdahl 2025) |
| Age | Younger age predicted better two-year response (Lovdahl 2025); an early series found only 25% of over-50s responded (Whorwell 1987) |
| Atypical presentations | In the same early series, classical cases responded at 95%, atypical at 43% (Whorwell 1987) |
Read those as tendencies in selected specialist caseloads, not as rules about you. The over-50s figure in particular comes from a 50-patient series published in 1987, before Rome criteria existed.
The counterpoint: the strongest case against it
An article that only stacks up positive trials is not worth reading, so here is the other side, made properly.
A Cochrane review could not reach a conclusion. Four studies totalling 147 patients met inclusion criteria. Data could not be pooled because of differences in outcome measures and design. The reviewers found hypnotherapy superior to waiting list or usual medical management for abdominal pain and composite symptoms in the short term, then concluded that the quality of the included trials was inadequate to allow any conclusion about efficacy (Webb 2007). That review is old, and much has been published since, but its methodological complaint has not gone away.
The pooled effect is fragile. The most recent delivery-focused meta-analysis found the overall effect on global symptoms non-significant, with substantial heterogeneity (Krouwel 2021). The 2025 network meta-analysis detected publication bias and found no trial at low risk of bias across all domains (Thakur 2025).
Blinding is impossible. You cannot give someone sham hypnotherapy without them noticing, and IBS endpoints are entirely self-reported. Every result in this article carries that discount. It is the same problem that afflicts diet trials in IBS, and it is why the field has had to write its own methodological standards (Burton-Murray 2025).
It is not the top-ranked option. Both recent networks place it below several other behavioural approaches, and the 2026 network places several drug classes above it (Khasawneh 2026).
It is not a treatment for a mechanical or biochemical cause. A sharp objection raised in one r/ibs thread was that promoting hypnotherapy as a remedy for specific food intolerances, bile acid malabsorption, carbohydrate malabsorption or bacterial overgrowth is unrealistic, because those are separate problems lumped under the IBS umbrella (r/ibs thread). That objection is correct, and no trial contradicts it.
None of this makes gut-directed hypnotherapy a bad option. It makes it a reasonable option with an uncertain effect size, which is a very different claim from the one on the sales pages.
What it cannot do, and when to see a doctor first
This is the part of the topic that carries actual risk, so it is worth being blunt.
Gut-directed hypnotherapy is a treatment for diagnosed IBS. It does not treat inflammation, it does not stop bleeding, it does not correct anaemia, and it will not explain unexplained weight loss. Offering it in place of investigating those things is a mistake regardless of how good the evidence for it is in the right population.
See a doctor promptly if you have any of these: blood in your stool or bleeding from the back passage, unexplained weight loss, fever, anaemia or a low iron result, symptoms that wake you from sleep, a change in bowel habit that starts after the age of 50, persistent vomiting, an abdominal or rectal mass, or a family history of bowel cancer, coeliac disease or inflammatory bowel disease. NICE lists red flag indicators that should prompt referral to secondary care before an IBS diagnosis is settled (NICE CG61).
The trial data give a concrete illustration. In the Dutch multicentre hypnotherapy trial, eight unexpected serious adverse reactions were reported among enrolled patients, most of which were cancer or inflammatory bowel disease, and the ethics committee judged them unrelated to the therapy (Flik 2019). These were people who had already been referred for psychological treatment of IBS. Assessment is not a formality.
One of the seed threads for this article is a person with three years of rectal bleeding whose new gastroenterologist opened with "so I understand you have a gut-brain disorder", focused on their anxiety, and was reluctant to order further imaging. Other commenters told them plainly that bleeding needs investigating (r/ibs thread). They were right. If you are in that position, our guides on whether to see a gastroenterologist and how to know if your IBS is flaring cover what to bring and what a reasonable answer sounds like.
Gut-directed hypnotherapy is generally very safe. Across eight randomised trials, one participant in 238 withdrew because of an adverse event, a panic attack (Schaefert 2014). Vendor guidance commonly advises against it for people with a history of psychosis. If your mood is the thing that has become unmanageable, that deserves direct help rather than a gut protocol: up to a third of people with IBS also experience anxiety or depression, and integrated care that addresses both is considered the better model (Staudacher 2023). If you are having thoughts of harming yourself, contact your local emergency number or a crisis line now rather than waiting for an appointment.
Getting hold of it: access, cost and the referral gate
The gap between "guideline-recommended" and "available" is the most common frustration in patient threads, and it is real.
NICE places referral for psychological interventions, including hypnotherapy, after twelve months of non-response to drug treatment (NICE CG61). That is a long gate, and local commissioning decides whether anything sits behind it. UK posters in r/ibs routinely report that their area offers nothing (r/ibs thread).
Even within specialist care, delivery is patchy. A 2026 UK study comparing 68 ethnic minority patients with 68 age and gender matched white British controls in one large teaching hospital found ethnic minority patients saw more clinicians and needed more appointments to reach a diagnosis, and were less likely to be recommended brain-gut behavioural therapies. Across both groups, adherence to national guidelines was low, with most patients not recommended second-line medical, dietary or behavioural treatment at all (Newman-Booth 2026). That is a single-centre study, and it describes a UK secondary care setting, but the headline finding is that the bottleneck is delivery, not evidence.
Cost drives most people toward apps. In the r/ibs discussions, quoted private session prices in North America ran to a few hundred dollars per session, against roughly eighty dollars for a three-month app subscription; others found even that too much alongside everything else IBS costs them (r/ibs thread). Group delivery is the underused middle option: it was non-inferior to individual hypnotherapy in the Dutch trial, and the authors noted explicitly that group therapy could allow many more patients to be treated for the same cost (Flik 2019). Nurse-led and online group formats are being tested for the same reason (Lovdahl 2026).
Practical questions worth asking a prospective practitioner: which IBS protocol do you use, how many sessions, what happens between sessions, what proportion of your IBS patients complete the course, and what do you do if there is no change by week six.
Myths about gut-directed hypnotherapy
"It works for 80% of people." That figure is a responder rate from an uncontrolled specialist audit of refractory patients who chose to attend twelve sessions (Miller 2015). The best controlled estimate in ordinary referred patients is around 41% against 17% on an attention-matched control (Flik 2019).
"It only works if you are suggestible." The audits did not find a clean personality predictor. What they found was that response was unaffected by bowel habit subtype and slightly higher in anxious patients, and that no pre-treatment variable explained the poor response in men with diarrhoea (Gonsalkorale 2002).
"Being offered it means your doctor thinks you are imagining it." IBS is classified as a disorder of gut-brain interaction rather than a functional disorder, a reclassification reflected in the British guideline (Vasant 2021). In the digital trial, gut symptoms and quality of life improved more in the hypnotherapy arm while psychological scores improved about equally in both, which is the opposite of what you would expect if the benefit were purely a mood effect (Anderson 2025).
"CBT and hypnotherapy are basically a cure for IBS." They are not. A widely upvoted r/ibs thread opens with a gastroenterologist telling a patient with fifteen bowel movements a day that IBS is "pretty curable with CBT"; almost every reply disagreed from experience, and several described therapy helping their mental health while their gut carried on unchanged (r/ibs thread). The trial literature agrees: these are treatments that improve symptoms in a proportion of people, not cures.
"An app is just a cheap imitation." The one randomised trial of a digital gut-directed hypnotherapy programme found it beat a matched control programme without the hypnotherapy (Anderson 2025), and that trial was funded by the app's manufacturer. Nobody has tested an app against a therapist in adults, so "as good as" and "much worse than" are both unsupported.
"If it did not work, I did it wrong." Course volume matters (Krouwel 2021) and adherence matters, but a substantial fraction of people complete a full protocol and get nothing. In the most rigorous trial, the majority of the hypnotherapy arm did not reach adequate relief (Flik 2019). A non-response is a result about the treatment, not about you.
The honest bottom line
Gut-directed hypnotherapy is a legitimate, guideline-recognised treatment for diagnosed IBS with four decades of trial evidence, an unusually good durability record and a very low adverse event rate. If your symptoms have persisted through dietary and drug approaches, it is a reasonable next thing to try, ideally as a full-volume course with daily practice and a proper before-and-after measurement.
It is also oversold. The famous 70 to 80% figure is a misread responder rate from an uncontrolled specialist audit. Controlled trials put the number closer to 40% with a control arm reaching the high teens to low twenties. Meta-analyses detect publication bias, find no trial at low risk of bias, and rank it below several other behavioural options. The mechanism is genuinely unsettled, and the confident vagus-nerve explanation on commercial pages outruns the physiology studies, one of which found no change in rectal sensitivity or autonomic function at all.
And it is the wrong tool for anything that has not been assessed. Bleeding, weight loss, fever, anaemia, night-time symptoms or a new change in bowel habit after 50 need a doctor promptly. Even inside a hypnotherapy trial, serious conditions surfaced among people already labelled as having IBS.
Try it with realistic expectations, measure it honestly, and stop if a full course does nothing. That is a better use of three months than another round of hope.
